{"filing":{"accession_number":"0001193125-26-336772","cik":"0001652130","ticker":"NTLA","company_name":"Intellia Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ntla-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/ntla-20260806.htm"},"events":[{"id":25555,"run_id":23196,"accession_number":"0001193125-26-336772","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes consolidated statements of operations showing net loss of $106.6 million for Q2 2026, balance sheet data, and business updates on clinical programs (lonvo-z Phase 3 positive results, nex-z enrollment progress). The press release is furnished as Exhibit 99.1 and contains standard financial metrics and operational highlights typical of an earnings announcement.","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26423,"accession_number":"0001193125-26-336772","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes consolidated statements of operations showing net loss of $106.6 million for Q2 2026, balance sheet data, and business updates on clinical programs (lonvo-z Phase 3 positive results, nex-z enrollment progress). The press release is furnished as Exhibit 99.1 and contains standard financial metrics and operational highlights typical of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:43.675014+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26423,"accession_number":"0001193125-26-336772","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes consolidated statements of operations showing net loss of $106.6 million for Q2 2026, balance sheet data, and business updates on clinical programs (lonvo-z Phase 3 positive results, nex-z enrollment progress). The press release is furnished as Exhibit 99.1 and contains standard financial metrics and operational highlights typical of an earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:54:43.675014+00:00","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-08-06"}]}